dc.creator | Anjani, Qonita Kurnia | es |
dc.creator | Pandya, Anjali K. | es |
dc.creator | Demartis, Sara | es |
dc.creator | Domínguez Robles, Juan | es |
dc.creator | Moreno Castellanos, Natalia | es |
dc.creator | Li, Huanhuan | es |
dc.creator | Gavini, Elisabetta | es |
dc.creator | Patravale, Vandana B. | es |
dc.creator | Donnelly, Ryan F. | es |
dc.date.accessioned | 2024-03-01T17:05:52Z | |
dc.date.available | 2024-03-01T17:05:52Z | |
dc.date.issued | 2023 | |
dc.identifier.citation | Anjani, Q.K., Pandya, A.K., Demartis, S., Domínguez Robles, J., Moreno Castellanos, N., Li, H.,...,Donnelly, R.F. (2023). Liposome-loaded Polymeric Microneedles for Enhanced Skin Deposition of Rifampicin. International Journal of Pharmaceutics, 646, 123446. https://doi.org/10.1016/j.ijpharm.2023.123446. | |
dc.identifier.issn | 0378-5173 | es |
dc.identifier.issn | 1873-3476 | es |
dc.identifier.uri | https://hdl.handle.net/11441/155764 | |
dc.description.abstract | Methicillin-resistant Staphylococcus aureus (MRSA) is a prevailing bacterial pathogen linked to superficial skin and soft tissue infections (SSTIs). Rifampicin (RIF), a potent antibiotic against systemic and localised staphylococcal infections, faces limitations due to its low solubility. This constraint hampers its therapeutic potential for MRSA-induced SSTIs. To address this, an advanced liposomal system was designed for efficient dermal RIF delivery. Rifampicin-loaded liposomes (LipoRIF) were embedded within polymeric dissolving microneedles (DMNs) to enable targeted intradermal drug delivery. A robust Design of Experiment (DoE) methodology guided the systematic preparation and optimisation of LipoRIF formulations. The optimal LipoRIF formulation integrated within polymeric DMNs. These LipoRIF-DMNs exhibited favourable mechanical properties and effective skin insertion characteristics. Notably, in vitro assays on skin deposition unveiled a transformative result – the DMN platform significantly enhanced LipoRIF deposition within the skin, surpassing LipoRIF dispersion alone. Moreover, LipoRIF-DMNs displayed minimal cytotoxicity toward cells. Encouragingly, rigorous in vitro antimicrobial evaluations demonstrated LipoRIF-DMNs' capacity to inhibit MRSA growth compared to the control group. LipoRIF-DMNs propose a potentially enhanced, minimally invasive approach to effectively manage SSTIs and superficial skin ailments stemming from MRSA infections. | es |
dc.description.sponsorship | Wellcome Trust WT094085MA | es |
dc.format | application/pdf | es |
dc.format.extent | 20 p. | es |
dc.language.iso | eng | es |
dc.publisher | Elsevier | es |
dc.relation.ispartof | International Journal of Pharmaceutics, 646, 123446. | |
dc.rights | Atribución 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.subject | Dissolving microneedles | es |
dc.subject | Liposome | es |
dc.subject | MRSA | es |
dc.subject | Rifampicin | es |
dc.subject | Skin infection | es |
dc.title | Liposome-loaded Polymeric Microneedles for Enhanced Skin Deposition of Rifampicin | es |
dc.type | info:eu-repo/semantics/article | es |
dc.type.version | info:eu-repo/semantics/publishedVersion | es |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es |
dc.contributor.affiliation | Universidad de Sevilla. Departamento de Farmacia y Tecnología Farmacéutica | es |
dc.relation.projectID | WT094085MA | es |
dc.relation.publisherversion | https://doi.org/10.1016/j.ijpharm.2023.123446 | es |
dc.identifier.doi | 10.1016/j.ijpharm.2023.123446 | es |
dc.journaltitle | International Journal of Pharmaceutics | es |
dc.publication.volumen | 646 | es |
dc.publication.initialPage | 123446 | es |
dc.contributor.funder | Wellcome Trust | es |